These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease. Stanton RC Semin Nephrol; 2021 Mar; 41(2):85-95. PubMed ID: 34140099 [TBL] [Abstract][Full Text] [Related]
17. Effect of purified glucagon (hyperglycemic-glycogenolytic factor, HGF) on carbohydrate and corticoid metabolism in normal and diabetic subjects. KIRTLEY WR; WAIFE SO; HELMER OM; PECK FB Diabetes; 1953; 2(5):345-9. PubMed ID: 13107530 [No Abstract] [Full Text] [Related]
18. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy. Sato A; Nishimoto M Hypertens Res; 2022 Aug; 45(8):1310-1321. PubMed ID: 35726084 [TBL] [Abstract][Full Text] [Related]
19. A renaissance in the treatment of diabetic kidney disease, hypertension in chronic kidney disease, and beyond. Yahr J; Calle J; Taliercio JJ J Osteopath Med; 2021 Oct; 122(1):55-63. PubMed ID: 34648702 [TBL] [Abstract][Full Text] [Related]